Dayanand Medical College and Hospital - Recruiting 18 years to 70 years. - Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial.
Conatus Pharmaceuticals Inc. - Recruiting 18 years or older. - A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure.
Theodor Bilharz Research Institute - Recruiting 25 years to 55 years. - Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis..
Hoffmann-La Roche - Recruiting 18 years or older. - Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice.
Gilead Sciences - Recruiting 18 years to 60 years. - A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety, and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2) in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).
Leiden University Medical Center - Recruiting 18 years to 75 years. - A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy.
Salix Pharmaceuticals - Recruiting 18 years or older. - A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis.
Placebo; Rifaximin SSD 40 mg IR tablet; Rifaximin SSD 80 mg IR tablet; Rifaximin SSD 40 mg SER tablet; Rifaximin SSD 80 mg SER tablet; Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet
KT&G Life Sciences Corp - Recruiting 20 years or older. - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis.
Sequana Medical AG - Recruiting 18 years or older. - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function in Patients With Cirrhosis and Recurrent or Refractory Ascites.
Asan Medical Center - Recruiting 20 years to 80 years. - Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver: Prospective Pathologic Correlation With Explanted Liver.
Seoul National University Hospital - Recruiting 20 years to 70 years. - Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy.
National Taiwan University Hospital - Recruiting 50 years to 70 years. - Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).
University Health Network, Toronto - Recruiting 18 years to 85 years. - Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease.